G1 Therapeutics sell quelbe60
Start price
24.06.24
/
50%
€2.25
Target price
24.06.25
-
Performance (%)
-2.31%
Price
14:34
€2.20
Summary
This prediction is currently active. With a performance of -2.31%, the SELL prediction by quelbe60 is trending in the right direction. This prediction currently runs until 24.06.25. The prediction end date can be changed by quelbe60 at any time. quelbe60 has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w |
|---|---|
| G1 Therapeutics | -2.31% |
| iShares Core DAX® | -0.079% |
| iShares Nasdaq 100 | 0.247% |
| iShares Nikkei 225® | 1.918% |
| iShares S&P 500 | 0.146% |
Comments by quelbe60 for this prediction
In the thread G1 Therapeutics diskutieren
Sell G1 Therapeutics